ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling

Baorui Tao(Huashan Hospital)
Clinical and Molecular Hepatology
January 20, 2026
Cited by 1


Related Papers

No related papers found

Powered by citation graph analysis